BMS withdraws Opdivo+Yervoy application

Bristol-Myers Squibb has withdrawn its application for FDA approval of a treatment that combined Opdivo with the drugmaker ' s other immune-oncology drug, Yervoy.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news